DURHAM, N.C., Jan. 15, 2015 (GLOBE NEWSWIRE) -- Heat Biologics, Inc. (“Heat”) (Nasdaq:HTBX), a clinical stage biopharmaceutical company focused on the development of cancer immunotherapies, today announced that Jeff Wolf, CEO, will present a corporate update at the Noble Financial Capital Markets Equity Conference, being held at Club Med in Sandpiper Bay, Florida on Monday, January 19, 2015 at 9:30am Eastern Time. Taylor Schrieber will also be participating in their Immunotherapy panel on January 19 at 5:00pm.
| Corporate Presentation details: | |
| Date and time: | Monday, January 19 @ 9:30am Eastern Time |
| Location: | Club Med in Sandpiper Bay, Florida |
| Webcast: | http://noble.mediasite.com/mediasite/Play/1994d1ce5af84790bef1558baf68170d1d |
| Panel Presentation Details | |
| Title: | Noble Immunotherapy Panel |
| Date and Time: | Monday, January 19 @ 5:00pm Eastern Time |
| Location: | Club Med in Sandpiper Bay, Florida |
About Heat Biologics, Inc.
Heat Biologics, Inc. (www.heatbio.com) is a clinical-stage biopharmaceutical company focused on developing its novel, “off-the-shelf” ImPACT therapeutic vaccines to combat a wide range of cancers. Our ImPACT Therapy is designed to deliver live, genetically-modified, irradiated human cells which are reprogrammed to “pump out” a broad spectrum of cancer-associated antigens together with a potent immune adjuvant called “gp96" to educate and activate a cancer patient’s immune system to recognize and kill cancerous cells. Heat is conducting a Phase 2 trial of its viagenpumatucel-L (HS-110) in patients with non-small cell lung cancer as well as a Phase 2 with its vesigenurtacel-L (HS-410) in patients with non-muscle invasive bladder cancer.
Forward Looking Statements
This press release includes forward-looking statements on our current expectations and projections about future events. In some cases forward-looking statements can be identified by terminology such as “may,” “should,” “potential,” “continue,” “expects,” “anticipates,” “intends,” “plans,” “believes,” “estimates,” and similar expressions. These statements are based upon current beliefs, expectations and assumptions and include statements regarding the potential for Heat’s ImPACT Therapy. These statements are subject to a number of risks and uncertainties, many of which are difficult to predict, including the ability for Heat’s ImPACT Therapy to perform as designed and ability to enroll patients as planned and the other factors described in our annual report on Form 10-K for the year ended December 31, 2013 and our other filings with the SEC. The information in this release is provided only as of the date of this release, and we undertake no obligation to update any forward-looking statements contained in this release based on new information, future events, or otherwise, except as required by law.
CONTACT: Heat Biologics, Inc. Contact Information: Matthew Czajkowski Chief Financial Officer (919) 240-7133 matt@heatbio.com Investor Relations Michael Wood LifeSci Advisors LLC (646) 597-6983
Help employers find you! Check out all the jobs and post your resume.
